GeoVax Labs Gains on Positive Regulatory Outlook

GeoVax Labs shares are trading higher after Alliance Global Partners reiterated a Buy rating and set an $8.50 price target, citing positive feedback from the European Medicines Agency on their GEO-MVA vaccine candidate.